Optimization Of Co-Amoxiclav Dosing Regimens Against Staphylococcus Aureus Using Pharmacokinetic/Pharmacodynamic Modeling: A Simulation-Based Approach
International Journal of Drug Delivery Technology · 30.06.2026 · 16 (65s)
DOI: 10.25258/ijddt.16.65s.51 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 30.06.2026. Verfasst von Vishwabhan Singh und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Antimicrobial resistance (AMR) is making it more difficult to treat Staphylococcus aureus infections. Inadequate dosing of co-amoxiclav, a commonly used β-lactam/β-lactamase inhibitor combination, may result in insufficient bacterial eradication and resistance selection. Nevertheless, there are still few evidence-based dosing strategies based on pharmacokinetic/pharmacodynamic (PK/PD) modeling. Using fT>MIC ≥40% as the efficacy target, this study sought to create a simulation-based PK/PD model for co-amoxiclav and assess the probability of target attainment (PTA) for oral and intravenous (IV) regimens across clinically relevant minimum inhibitory concentration (MIC) ranges for methicillinsensitive S. aureus (MSSA). Peer-reviewed literature and validated pharmacological databases provided pharmacokinetic parameters. R software (v4.x) was used to integrate a two-compartment PK model with an Emax pharmacodynamic model. 50 virtual adult subjects with 30% inter-individual variability in clearance, volume of distribution, and absorption rate constant were used in population simulations. Oral and IV dosing regimens (500–2,000 mg) were simulated at intervals of 6, 8, 12, and 24 hours, and PTA was measured over MIC values ranging from 0.5 to 8 μg/mL. Regression analysis showed a strong correlation between dose and fT>MIC (R² >0.88), and ANOVA confirmed statistically significant differences among dosing regimens (p90% was achieved for MSSA isolates with MIC ≤4 μg/mL using oral doses of 1,000–1,500 mg administered every 6–8 hours and IV doses of 1,000–1,500 mg every 6 hours. Although additional clinical validation is necessary, PK/PD modeling generally supports the use of co-amoxiclav at doses of 1,000– 1,500 mg every 6–8 hours (oral) and every 6 hours (IV) for MSSA infections with MIC ≤4 μg/mL. This provides a quantitative basis for optimizing dosing strategies and minimizing subtherapeutic exposure.
Zitieren
APA
Singh, V., Darji, V. C., Bariya, A. H., Patel, V. M., Christian, P. G., Modi, I. A., & Kwalli, M. A. (2026). Optimization Of Co-Amoxiclav Dosing Regimens Against Staphylococcus Aureus Using Pharmacokinetic/Pharmacodynamic Modeling: A Simulation-Based Approach. International Journal of Drug Delivery Technology, 16(65s). https://doi.org/10.25258/ijddt.16.65s.51
Vancouver
Singh V, Darji VC, Bariya AH, Patel VM, Christian PG, Modi IA, et al. Optimization Of Co-Amoxiclav Dosing Regimens Against Staphylococcus Aureus Using Pharmacokinetic/Pharmacodynamic Modeling: A Simulation-Based Approach. International Journal of Drug Delivery Technology. 2026;16(65s). doi:10.25258/ijddt.16.65s.51
BibTeX
@article{Singh2026,
author = {Singh, Vishwabhan and Darji, Vinay C. and Bariya, Aditi H. and Patel, Vaibhavi M. and Christian, Prarthna G and Modi, Ishangi A and Kwalli, Musa Abdulaziz},
title = {Optimization Of Co-Amoxiclav Dosing Regimens Against Staphylococcus Aureus Using Pharmacokinetic/Pharmacodynamic Modeling: A Simulation-Based Approach},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {65s},
doi = {10.25258/ijddt.16.65s.51}
}
EUVIMED